Drug Profile

Research programme: biologic therapeutics - Ducentis BioTherapeutics

Alternative Names: CD200 program; Research programme: CD200 variants - Ducentis BioTherapeutics

Latest Information Update: 13 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

13 Sep 2022 Ducentis BioTherapeutics has patent protection for CD200 variants in multiple countries including the US and Japan (Ducentis BioTherapeutics website, September 2022)
07 Sep 2022 Preclinical trials in Autoimmune disorders in United Kingdom (unspecified route) before September 2022
07 Sep 2022 Preclinical trials in Inflammation in United Kingdom (unspecified route) before September 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com